(Re)situating expertise in community-based overdose response: Insights from an ethnographic study of overdose prevention sites (OPS) in Vancouver, Canada.

Ethnography Expertise Opioid overdose Overdose education and response Peer workers People who use drugs Qualitative research

Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 06 07 2022
revised: 20 10 2022
accepted: 02 12 2022
pmc-release: 01 01 2024
pubmed: 19 12 2022
medline: 25 1 2023
entrez: 18 12 2022
Statut: ppublish

Résumé

Overdose Prevention Sites (OPS) are low-barrier services where people may use illicit drugs under the monitoring of staff trained to provide life-saving care in the event of an overdose. In British Columbia (BC), Canada, OPS have been rapidly scaled-up as a community-based response to the overdose crisis and are staffed primarily by community members who are also people who use drugs (PWUD). While it is known that PWUD perform vital roles in OPS and other community-based overdose interventions, the expertise and expert knowledge of PWUD in this work remains under-theorised. This study draws on 20 months of ethnographic fieldwork in Vancouver, BC (July 2018 to March 2020), to explore how OPS responders who are PWUD developed and enacted expertise in overdose response. Ethnographic fieldwork focused on four OPS located in Vancouver's Downtown Eastside (DTES) and Downtown South neighbourhoods. Methods included 100 hours of observation in the sites and surrounding areas, three site-specific focus groups with OPS responders (n=20), and semi-structured interviews with OPS responders (n=14) and service users (n=23). Data was analysed with the aim of characterizing the knowledge underpinning responders' expertise, and the arrangements which allow for the formation and enactment of expertise. We found that OPS responders' expertise was grounded in experiential knowledge acquired through their positionality as PWUD and members of a broader community of activists engaged in mutual aid. Responders became skilled in overdose response through frequent practice and drew on their experiential and embodied knowledge of overdose to provide care that was both technically proficient and responsive to the broader needs of PWUD (e.g. protection from criminalization and stigmatizing treatment). Responders emphasized that the spatial arrangements of OPS supported the development of expertise by facilitating more specialized and comprehensive overdose care. OPS became sites of collective expertise around overdose management as responder teams developed shared understandings of overdose management, including processes for managing uncertainty, delegating team responsibilities, and sharing decision-making. This research re-situates theoretical understandings of expertise in community-based overdose response with implications for overdose prevention interventions. Findings underscore the experiential and embodied expertise of PWUD as community-based responders; the importance of supportive environments and team-based approaches for overdose response; and the benefits of community-driven training that extends beyond technical skills of overdose identification and naloxone administration.

Identifiants

pubmed: 36529032
pii: S0955-3959(22)00345-0
doi: 10.1016/j.drugpo.2022.103929
pmc: PMC10184134
mid: NIHMS1859172
pii:
doi:

Substances chimiques

Naloxone 36B82AMQ7N
Illicit Drugs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103929

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA044181
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of Interest None.

Références

Int J Drug Policy. 2020 Feb;76:102617
pubmed: 31838246
Lancet Public Health. 2022 Mar;7(3):e196-e197
pubmed: 35247348
Addiction. 2016 Jul;111(7):1177-87
pubmed: 27028542
J Urban Health. 2019 Feb;96(1):12-20
pubmed: 30073598
J Community Health. 2013 Feb;38(1):133-41
pubmed: 22847602
Drug Alcohol Depend. 2015 Dec 1;157:112-20
pubmed: 26507172
Br J Anaesth. 2003 Sep;91(3):319-28
pubmed: 12925468
Am J Public Health. 2009 May;99(5):788-91
pubmed: 19363214
BMJ. 1996 Jun 8;312(7044):1435-6
pubmed: 8664611
Addiction. 2008 Oct;103(10):1648-57
pubmed: 18821875
N Engl J Med. 2020 Aug 6;383(6):589-590
pubmed: 32640126
Int J Drug Policy. 2015 Jan;26(1):92-9
pubmed: 25130869
J Addict Med. 2014 May-Jun;8(3):153-63
pubmed: 24874759
Int J Drug Policy. 2017 Mar;41:19-28
pubmed: 28027483
Harm Reduct J. 2009 Sep 25;6:26
pubmed: 19781073
JAMA Netw Open. 2022 Jul 1;5(7):e2222153
pubmed: 35838675
Harm Reduct J. 2022 Feb 23;19(1):18
pubmed: 35197057
Int J Drug Policy. 2019 Apr;66:64-72
pubmed: 30708237
Sociol Health Illn. 2019 Feb;41(2):427-443
pubmed: 30710415
J Subst Abuse Treat. 2006 Mar;30(2):129-33
pubmed: 16490676
Harm Reduct J. 2017 Jun 7;14(1):34
pubmed: 28592287
Soc Sci Med. 2014 Apr;106:151-8
pubmed: 24561777
Subst Use Misuse. 2008;43(7):858-70
pubmed: 18570021
Drug Alcohol Depend. 2015 Jun 1;151:1-14
pubmed: 25891234
J Adv Nurs. 2018 Apr;74(4):818-826
pubmed: 29082581
Prev Med. 2019 Nov;128:105813
pubmed: 31437462
PLoS One. 2020 Sep 28;15(9):e0239559
pubmed: 32986736
Int J Drug Policy. 2021 Nov;97:103296
pubmed: 34062289
Addiction. 2018 Dec;113(12):2261-2270
pubmed: 30211453
Int J Drug Policy. 2014 Jan;25(1):157-65
pubmed: 23932166
BMJ. 2001 Apr 14;322(7291):895-6
pubmed: 11302902
Soc Sci Med. 2017 May;180:20-27
pubmed: 28315595
Soc Sci Med. 2014 Mar;105:59-66
pubmed: 24508718
Addiction. 2008 Jun;103(6):979-89
pubmed: 18422830
Nurs Educ Perspect. 2010 Mar-Apr;31(2):106-8
pubmed: 20455368
JAMA. 1999 Sep 1;282(9):833-9
pubmed: 10478689
Am J Public Health. 2022 Apr;112(S2):S191-S198
pubmed: 35349325
J Addict Dis. 2007;26(4):63-8
pubmed: 18032233
Int J Drug Policy. 2022 Jun;104:103670
pubmed: 35523063
Health Place. 2020 Jul;64:102376
pubmed: 32838893
Soc Sci Med. 2014 Feb;103:126-133
pubmed: 24507917
Drug Alcohol Depend. 2018 Jul 1;188:370-376
pubmed: 29776688
AIDS Behav. 2014 Mar;18(3):473-85
pubmed: 23797831
Addiction. 2019 Apr;114(4):708-718
pubmed: 30476356
Lancet. 2011 Apr 23;377(9775):1429-37
pubmed: 21497898
BMJ Open. 2019 Oct 28;9(10):e030046
pubmed: 31662368
Drug Alcohol Depend. 2005 Aug 1;79(2):181-90
pubmed: 16002027
Soc Sci Med. 2019 Mar;225:60-68
pubmed: 30798157
Drug Alcohol Rev. 2002 Sep;21(3):269-74
pubmed: 12270078
J Addict Dis. 2006;25(3):89-96
pubmed: 16956873
Soc Sci Med. 2005 Jun;60(11):2575-84
pubmed: 15814182
Int J Environ Res Public Health. 2021 Nov 17;18(22):
pubmed: 34831839
J Urban Health. 2011 Dec;88(6):1020-30
pubmed: 21773877
Int J Drug Policy. 2019 Dec;74:26-32
pubmed: 31442677
Am J Public Health. 2020 Jun;110(6):833-835
pubmed: 32298171
Addict Behav. 2006 May;31(5):907-12
pubmed: 16139434
Am J Public Health. 2022 Apr;112(S2):S136-S139
pubmed: 35349317
Harm Reduct J. 2021 Jun 5;18(1):60
pubmed: 34090473
Addiction. 2005 Mar;100(3):397-404
pubmed: 15733253
Soc Sci Med. 2021 Feb;270:113631
pubmed: 33418149
Implement Sci. 2008 May 29;3:29
pubmed: 18510749
J Am Assoc Nurse Pract. 2020 Apr 1;33(4):294-303
pubmed: 32251033
Int J Drug Policy. 2015 May;26(5):492-500
pubmed: 25630481
Int J Drug Policy. 2019 Nov;73:135-140
pubmed: 31654936
PLoS One. 2020 May 21;15(5):e0229208
pubmed: 32438390
Int J Drug Policy. 2010 May;21(3):186-93
pubmed: 19268564
Int J Drug Policy. 2018 Jun;56:56-63
pubmed: 29605706
Harm Reduct J. 2008 Jan 24;5:2
pubmed: 18218071
BMJ Open. 2019 Sep 12;9(9):e028583
pubmed: 31515417
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Subst Abus. 2016;37(1):76-81
pubmed: 26514071
Int J Drug Policy. 2020 Feb;76:102641
pubmed: 31887644
Int J Drug Policy. 2019 Dec;74:127-135
pubmed: 31590088

Auteurs

Michelle Olding (M)

British Columbia Centre on Substance Use, 1045 Howe Street, Vancouver, BC, V6Z 1Y6, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Jade Boyd (J)

British Columbia Centre on Substance Use, 1045 Howe Street, Vancouver, BC, V6Z 1Y6, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Thomas Kerr (T)

British Columbia Centre on Substance Use, 1045 Howe Street, Vancouver, BC, V6Z 1Y6, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Al Fowler (A)

East Vancouver Activist, Vancouver, BC, Canada.

Ryan McNeil (R)

British Columbia Centre on Substance Use, 1045 Howe Street, Vancouver, BC, V6Z 1Y6, Canada; Yale School of Medicine, New Haven, CT, United States. Electronic address: ryan.mcneil@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH